Search





Search





Markets
/
Stocks
/
nasdaq-gral
/

Grail Inc

GRAL

Add to Watchlist

61.260USD

-0.380-0.62%

Close 05/11, 16:00（ET）Quotes delayed by 15 min

2.52BMarket Cap

LossP/E TTM



Grail Inc

61.260

-0.380-0.62%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Grail Inc

Currency: USD Updated: 2026-05-08

Key Insights

Grail Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 33 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 67.71.In the medium term, the stock price is expected to trend down.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Grail Inc's Score

Industry at a Glance

Industry Ranking

33 / 384

Overall Ranking

129 / 4494

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Grail Inc Highlights

StrengthsRisks

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 58.07% year-on-year.

Undervalued

The company’s latest PE is -5.55, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 30.84M shares, decreasing 3.31% quarter-over-quarter.

Held by Murray Stahl

Star Investor Murray Stahl holds 5.24K shares of this stock.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

66.857

Target Price

+8.46%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-08

The current financial score of Grail Inc is 7.41, ranking 90 out of 384 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 43.60M, representing a year-over-year increase of 13.97%, while its net profit experienced a year-over-year increase of 2.17%.

Score

Industry at a Glance

Previous score

7.41

Change



Financials

6.15

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.37

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.32

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.20

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Grail Inc's Company Valuation

Currency: USD Updated: 2026-05-08

The current valuation score of Grail Inc is 7.47, ranking 111 out of 384 in the Biotechnology & Medical Research industry. Its current P/E ratio is -5.55, which is -97.68% below the recent high of -0.13 and -96.21% above the recent low of -10.89.

Score

Industry at a Glance

Previous score

7.47

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 33/384

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-08

The current earnings forecast score of Grail Inc is 8.00, ranking 161 out of 384 in the Biotechnology & Medical Research industry. The average price target is 105.00, with a high of 110.00 and a low of 100.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

66.857

Target Price

+8.46%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Grail Inc

GRAL

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-08

The current price momentum score of Grail Inc is 9.51, ranking 22 out of 384 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 69.17 and the support level at 49.63, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.71

Change

-0.2

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(1)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

2.834

Buy

RSI(14)

61.725

Neutral

STOCH(KDJ)(9,3,3)

83.363

Overbought

ATR(14)

3.722

High Vlolatility

CCI(14)

157.421

Buy

Williams %R

19.575

Overbought

TRIX(12,20)

0.559

Sell

StochRSI(14)

77.197

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

59.474

Buy

MA10

56.282

Buy

MA20

53.612

Buy

MA50

51.175

Buy

MA100

72.219

Sell

MA200

67.346

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-08

The current institutional shareholding score of Grail Inc is 7.00, ranking 79 out of 384 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 71.87%, representing a quarter-over-quarter increase of 8.35%. The largest institutional shareholder is The Vanguard, holding a total of 1.93M shares, representing 4.50% of shares outstanding, with 8.54% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

2.49M

+17.35%

Farallon Capital Management, L.L.C.

2.34M

+45.63%

Baker Bros. Advisors LP

2.09M

+27.92%

PRIMECAP Management Company

Star Investors

1.84M

-9.02%

State Street Investment Management (US)

1.83M

+38.77%

Illumina Inc

1.30M

-62.82%

CRCM L.P.

1.07M

-40.45%

Arbiter Partners Capital Management, LLC

1.04M

-0.03%

Deep Track Capital LP

1.02M

Risk Assessment

Currency: USD Updated: 2026-05-08

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Grail Inc is 3.64, ranking 123 out of 384 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.